コメントを投稿するにはログインが必要です
ログインページへ記事ができると、章ごとの要約と、聴きどころへ飛べる目次がここに並びます。いまは音声で聴けます。
#5-95E. Reassuring Evidence: Malignancy Risk in IgG4-Related Disease (Ann Rheum Dis, 2026)
2026年10月14日 12:00·6分22秒
Does an IgG4-related disease (IgG4-RD) diagnosis truly elevate long-term cancer risk? In a single-center retrospective cohort study of 348 patients followed over a median of eight years, incident malignancy rates were comparable to the general population (standardized incidence ratio, 0.88), with submandibular gland involvement surprisingly linked to lower risk. Although this study's single-center design in a predominantly White cohort limits generalizability, these findings reassure clinicians that IgG4-RD itself is not oncogenic. Consequently, physicians can counsel patients confidently without ordering excessive cancer screenings.
Citation: Michelson DA, McMahon GA, Jha I, Jiang B, Zhang Y, Fernandes AD, Stone JH, Wallace ZS, Katz G. IgG4-related disease is not associated with an increased incidence of malignancy in a large, single-centre cohort. Annals of the Rheumatic Diseases. 2026.
URL: https://doi.org/10.1016/j.ard.2026.08.012
Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.
